25023-36-3

Basic information

• Product Name: (2-METHYL-IMIDAZOL-1-YL)-ACETIC ACID
• Synonyms: (2-METHYL-IMIDAZOL-1-YL)-ACETIC ACID;(2-METHYL-1H-IMIDAZOL-1-YL)ACETIC ACID;CHEMBRDG-BB 4009535;(2-methyl-1H-imidazol-1-yl)acetic acid(SALTDATA: HCl);2-(2-Methyl-1H-iMidazol-1-yl)acetic acid hydrochloride;2-(2-methyl-1-imidazolyl)acetic acid;2-(2-methylimidazol-1-yl)acetic acid;2-(2-methylimidazol-1-yl)ethanoic acid
• CAS NO: 25023-36-3
• Molecular Formula: C₆H₈N₂O₂
• Molecular Weight: 140.14
• Mol File: 25023-36-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 367.9°Cat760mmHg
• Flash Point: 176.3°C
• Appearance: /
• Density: 1.27g/cm³
• Vapor Pressure: 4.62E-06mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: (2-METHYL-IMIDAZOL-1-YL)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (2-METHYL-IMIDAZOL-1-YL)-ACETIC ACID(25023-36-3)
• EPA Substance Registry System: (2-METHYL-IMIDAZOL-1-YL)-ACETIC ACID(25023-36-3)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 25023-36-3(Hazardous Substances Data)

Usage

General Description

(2-Methyl-imidazol-1-yl)-acetic acid, also known as histidine, is an organic compound that is commonly found in proteins and is considered an essential amino acid for human health. It is a key component of hemoglobin and is important for maintaining the balance of acids and bases in the body. Histidine is also involved in the synthesis of histamine, a compound that plays a role in the immune response and acts as a neurotransmitter. In addition, histidine has antioxidant properties and has been studied for its potential role in treating conditions such as rheumatoid arthritis and allergies. Overall, (2-Methyl-imidazol-1-yl)-acetic acid is an important molecule for various physiological functions in the body.

InChI:InChI=1/C6H8N2O2/c1-5-7-2-3-8(5)4-6(9)10/h2-3H,4H2,1H3,(H,9,10)

Upstream product

• 693-98-1 2-methylimidazole 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 1448308-96-0 N-(3-(1,3,4-oxadiazol-2-yl)phenyl)-N-(1-(2-chlorophenyl)-2-(cyclohexylamino)-2-oxoethyl)-2-(2-methyl-1H-imidazol-1-yl)acetamide 

Relevant articles and documents

Pharmacological evaluation of imidazole-derived bisphosphonates on receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation and function

Bisphosphonates (BPs) have been commonly used in the treatment of osteolytic bone lesions, such as osteoporosis and osteogenesis imperfecta. However, serious side-effects can occur during the therapy. To search for novel potent BPs with lower side-effects, a series of imidazole-containing BPs (zoledronic acid [ZOL]; ZOL derivatives by substitution of the hydrogen at the 2-position on the imidazole ring with a methyl [MIDP], ethyl [EIDP], n-propyl [PIDP], or n-butyl group [BIDP]) were developed and the effects on receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation were investigated using the murine macrophage RAW 264.7 cells at the protein, gene, and morphological and functional levels. Influences of these BPs on the cell growth and proliferation of RAW 264.7 were also studied in order to determine cytotoxicity. The results showed that PIDP significantly inhibited the RANKL-induced osteoclast formation in a dose-dependent fashion without inducing cytotoxicity under the concentration of 12.5?μM. It exerted remarkable suppressive effects on the development of actin rings, the bone resorption, and the expressions of osteoclastogenesis-related gene and protein markers. The down-regulation of c-Jun N-terminal kinase (JNK), protein kinase B (Akt), and inhibitor of nuclear factor kappa-B (IκB) phosphorylation in the early signaling event and subsequent inhibition of the expression of c-Fos and nuclear factor of activated T cells (NFATc1) might be involved in these effects. All these results indicated that PIDP might be a promising drug to treat bone-related disorders.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.